Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.47M | 69.64M | 49.80M | 70.86M | 58.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.47M | 69.64M | 49.80M | 70.86M | 58.43M |
| Cost of Revenue | 5.80M | 4.10M | 6.56M | -1.73M | 5.36M |
| Gross Profit | 35.67M | 65.55M | 43.24M | 72.59M | 53.08M |
| SG&A Expenses | 35.34M | 34.94M | 37.32M | 60.82M | 92.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.97M | 93.87M | 98.71M | 136.63M | 175.71M |
| Operating Income | -54.50M | -24.23M | -48.91M | -65.77M | -117.27M |
| Income Before Tax | -61.12M | -26.09M | -50.34M | -68.58M | -120.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.12 | -26.09 | -50.34 | -68.58 | -120.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.12M | -26.09M | -50.34M | -68.58M | -120.62M |
| EBIT | -54.50M | -24.23M | -48.91M | -65.77M | -117.27M |
| EBITDA | -54.02M | -23.67M | -48.29M | -65.14M | -116.67M |
| EPS Basic | -0.15 | -0.07 | -0.14 | -0.19 | -0.33 |
| Normalized Basic EPS | -0.09 | -0.04 | -0.09 | -0.12 | -0.21 |
| EPS Diluted | -0.15 | -0.07 | -0.14 | -0.19 | -0.33 |
| Normalized Diluted EPS | -0.09 | -0.04 | -0.09 | -0.12 | -0.21 |
| Average Basic Shares Outstanding | 1.56B | 1.49B | 1.45B | 1.45B | 1.45B |
| Average Diluted Shares Outstanding | 1.56B | 1.49B | 1.45B | 1.45B | 1.45B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |